[Hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis arising from gastric cancer].
Since 20 years, treatment of peritoneal carcinomatosis has been developed in expert centers. Cytoreductive surgery and perioperative intraperitoneal chemotherapy, especially hyperthermic intraperitoneal chemotherapy, was assessed by many nonrandomised studies for the treatment of peritoneal carcinomatosis arising from gastric cancer. Results described increased survival, especially for the most favourable cases: limited carcinomatosis and complete cytoreductive surgery. A strict selection of the patients is necessary because of the important morbidity of those treatments. Only patients with good general health, able to tolerate a threatening treatment, with possible complete cytoreduction, may benefit from those treatments. Many japanese studies had demonstrated the efficacy of hyperthermic intraperitoneal chemotherapy for the prophylactic treatment of carcinomatosis in advanced-gastric cancers. These results have to be confirmed by european randomised studies.
Cotte
E
E
Service de chirurgie générale, thoracique et endocrinienne, centre hospitalo-universitaire Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France.
Gilly
F-N
FN
Beaujard
A-C
AC
Glehen
O
O
D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D007414:Intestinal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D013274:Stomach Neoplasms / Q000150:complications / Q000473:pathology*